Ligands, their receptors and ... plasma membranes

Molecular and Cellular Endocrinology

Volumn 311, Issue 1-2, 2009, Pages 1-10

  Vauquelin, G ^a   Packeu, A ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Affinity; Binding kinetics; Conformation; Diffusion; Exosites; Ligands; Partitioning; Plasma membranes; Receptors; Residence time

Indexed keywords

SALMETEROL;

ALPHA HELIX; BILAYER MEMBRANE; BINDING KINETICS; BIOPHYSICS; CATALYSIS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DIFFUSION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SCREENING; GENE MUTATION; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW;

ANIMALS; CELL MEMBRANE; HUMANS; LIGANDS; LIPID BILAYERS; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, CELL SURFACE; TIME FACTORS;

EID: 69249210978     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.07.022     Document Type: Review

References (85)

1. Adam G., and Delbrück M. Reduction of dimensionality in biological diffusion processes. In: Rich A., Davidson N., and Freeman W.H. (Eds). Structural Chemistry and Molecular Biology (1968), W.H. Freeman & Co., San Francisco 198-215
2. Aiello M., Moran O., Pisciotta M., and Gambale F. Interaction between dihydropyridines and phospholipid bilayers: a molecular dynamics simulation. Eur. Biophys. J. 27 (1998) 211-218
3. Anderson G.P. In: Anderson G.P., Chapman I.D., and Morley J. (Eds). In New Drugs for Asthma Therapy. Agents and Actions Supplement vol. 34 (1991), Birkhauser Verlag 97-115
4. 2-adrenoceptor agonist bronchodilator. Life Sci. 52 (1993) 2145-2160
5. Anderson G.P., Lindén A., and Rabe K.F. Why are long-acting beta-adrenoceptor agonists long-acting?. Eur. Respir. J. 7 (1994) 569-578
6. 2-adrenoceptor agonists. J. Med. Chem. 46 (2003) 3210-3320
7. Axelrod D. New dimensions in two dimensions. Biophys. J. 67 (1994) 1799-1800
8. Axelrod D., and Wang M.D. Reduction-of-dimensionality kinetics at reaction-limited cell surface receptors. Biophys. J. 66 (1994) 588-600
9. Bader R., Bettio A., Beck-Sickinger A.G., and Zerbe O. Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection. J. Mol. Biol. 305 (2001) 307-329
10. Ball D.I., Brittain R.T., Coleman R.A., Denyer L.H., Jack D., Johnson M., Lunts L.H., Nials A.T., Sheldrick K.E., and Skidmore I.F. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br. J. Pharmacol. 104 (1991) 665-671
11. Bangalore R., Baindur N., Rutledge A., Triggle D.J., and Kass R.S. L-type calcium channels: asymmetrical intramembrane binding domain revealed by variable length, permanently charged 1,4-dihydropyridines. Mol. Pharmacol. 46 (1994) 660-666
12. Barnett-Norris J., Lynch D., and Reggio P.H. Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci. 77 (2005) 1625-1639
13. Berg H.C., and Purcell E.M. Physics of chemoreception. Biophys. J. 20 (1977) 193-219
14. Bergendal A., Lindén A., Skoogh B.E., Gerspacher M., Anderson G.P., and Lolfdahl C.G. Salmeterol mediated reassertion of relaxation persists in guinea-pig trachea pretreated with aliphatic side chain structural analogues. Br. J. Pharmacol. 117 (1996) 1009-1015
15. Bokvist M., Lindstrom F., Watts A., and Grobner G. Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J. Mol. Biol. 335 (2004) 1039-1049
16. Brown A.M., Kunze D.L., and Yatani A. The agonist effect of dihydropyridines on Ca channels. Nature 311 (1984) 570-572
17. Castanho M.A.R.B., and Fernandes M.X. Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the "membrane catalysis" model. Eur. Biophys. J. 35 (2006) 92-103
18. Chester D.W., Herbette L.G., Mason R.P., Joslyn A.F., Triggle D.J., and Koppel D.E. Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers. Biophys. J. 52 (1987) 1021-1030
19. 1 muscarinic acetylcholine receptor. Mol. Pharmacol. 53 (1998) 1120-1130
20. Clark R.B., Allal C., Friedman J., Johnson M., and Barber R. Stable activation and desensitization of beta 2-adrenergic receptor simulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Mol. Pharmacol. 49 (1996) 182-189
21. 2-adrenoceptor agonists. Trends Pharmacol. Res. 17 (1996) 324-330
22. Contreras L.L., de Almeida R.F.M., Villalaín J., Fedorov A., and Prieto M. Interaction of α-melanocyte stimulating hormone with binary phospholipid membranes: structural changes and relevance of phase behavior. Biophys. J. 80 (2001) 2273-2283
23. Coombs D., and Goldstein B. Effects of the geometry of the immunological synapse on the delivery of effector molecules. Biophys. J. 87 (2004) 2215-2220
24. Copeland R.A., Pompliano D.L., and Meek T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5 (2006) 730-739
25. DeLisi C. The effect of cell size and receptor density on ligand-receptor reaction rate constants. Mol. Immunol. 18 (1981) 507-511
26. DeLisi C., and Wiegel F.W. Effect of nonspecific forces and finite receptor number on rate constants of ligand-cell bound-receptor interactions. Proc. Natl. Acad. Sci. 78 (1981) 5569-5572
27. Eigen M. Diffusion control in biochemical reactions. In: Mintz S.L., and Widmayer S.N. (Eds). Quantum Statistical Mechanics in the Natural Sciences (1974), Plenum Press, New York 37-61
28. Erne D., Rolka K., and Schwyzer R. Membrane structure of substance P. III. Secondary structure of substance P in 2,2,2-trifluoroethanol, methanol, and on flat lipid membranes studied by infrared spectroscopy. Helv. Chim. Acta 69 (1986) 1807-1816
29. 3H]candesartan to intact cells and membrane preparations. Biochem. Pharmacol. 63 (2002) 1273-1279
30. Green S.A., Spasoff A.P., Coleman R.A., Johnson M., and Liggett S.B. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the β2-adrenergic receptor. J. Biol. Chem. 271 (1996) 24029-24035
31. Greff D., Thoma F., Fermandjian S., Löw M., and Kisfaludy L. Conformational studies of corticotropin1-32 and constitutive peptides by circular dichroism. Biochim. Biophys. Acta 439 (1976) 219-231
32. Gremlich H.U., Fringeli U.P., and Schwyzer R. Conformational changes of adrenocorticotropin peptides upon interaction with lipid membranes revealed by infrared attenuated total reflection spectroscopy. Biochemistry 22 (1983) 4257-4264
33. Hara M., Tozawa F., Itazaki K., Mihara S., and Fujimoto M. Endothelin ET(B) receptors show different binding profiles in intact cells and cell membrane preparations. Eur. J. Pharmacol. 345 (1998) 339-342
34. Herbette L.G., Trumbore M., Chester D.W., and Katz A.M. Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone. J. Mol. Cell. Cardiol. 20 (1988) 373-378
35. Herbette L.G. Membrane pathways for drug/ion channel interactions: molecular basis for pharmacokinetic properties. Drug Dev. Res. 33 (1994) 214-224
36. Hrabetová S., and Nicholson C. Contribution of dead-space microdomains to tortuosity of brain extracellular space. Neurochem. Int. 45 (2004) 467-477
37. 1 muscarinic acetylcholine receptor. J. Pharmacol. Exp. Ther. 301 (2002) 1033-1041
38. 1 receptors. J. Pharmacol. Exp. Ther. 308 (2004) 105-110
39. Johnson M., Butchers P.R., Coleman R.A., Nials A.T., Strong P., Sumner M.J., Vardey C.J., and Whelan C.J. The pharmacology of salmeterol. Life Sci. 52 (1993) 2131-2143
40. 2-Adrenoceptor Agonists (1995), Asthma & Rhinitis, Cambridge, Blackwell 1278-1295
41. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 117 (2006) 18-24
42. Kaiser E.T., and Krzdy F.J. Amphiphilic secondary structure: design of peptide hormones. Science (Wash., DC) 223 (1984) 249-255
43. Kapur A., Hurst D.P., Fleischer D., Whitnell R., Thakur G.A., Makriyannis A., Reggio P.H., and Abood M.E. Mutation studies of Ser7.39 and Ser2. 60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol. Pharmacol. 71 (2007) 1512-1524
44. Kokubun S., and Reuter H. Dihydropyridine derivatives prolong the open state of Ca channels in cultured cardiac cells. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 4824-4827
45. Lindén A., Bergendal A., Ullman A., Skoogh B.E., and Löfdahl C.G. High concentration of formoterol and salmeterol in the isolated guinae-pig trachea: reassertion of smooth muscle relaxation after beta blockade followed by wash-out. Am. Rev. Respir. Dis. 143 4(2) (1991) A749
46. Lovich M.A., Creel C., Hong K., Hwang C.W., and Edelman E.R. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J. Pharm. Sci. 90 (2001) 1324-1335
47. Lutz J., Romano-Götsch R., Escrieut C., Fourmy D., Mathä B., Müller G., Kessler H., and Moroder L. Mapping of ligand binding sites of the cholecystokinin-B/gastrin receptor with lipo-gastrin peptides and molecular modeling. Biopolymers 41 (1997) 799-817
48. Lynch D.L., and Reggio P.H. Molecular dynamics simulations of the endocannabinoid N-arachidonoylethanolamine (anandamide) in a phospholipid bilayer: probing structure and dynamics. J. Med. Chem. 48 (2005) 4824-4833
49. 1 transmembrane helix 6 and anandamide in a phospholipid bilayer. J. Comput. Aided Mol. Des. 20 (2006) 495-509
50. Mason R.P., Moring J., and Herbette L.G. A molecular model involving the membrane bilayer in the binding of lipid soluble drugs to their receptors in heart and brain. Int. J. Rad. Appl. Instrum. B 17 (1990) 13-33
51. Mason R.P., Rhodes D.G., and Herbette L.G. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J. Med. Chem. 34 (1991) 869-877
52. Makriyannis A., Tian X., and Guo J. How lipophilic cannabinergic ligands reach their receptor sites. Prostaglandins Other Lipid Mediat. 77 (2005) 210-218
53. Mavromoustakos T., Zoumpoulakis P., Kyrikou I., Zoga A., Siapi E., Zervou M., Daliani I., Dimitriou D., Pitsas A., Kamoutsis C., and Laggner P. Efforts to understand the molecular basis of hypertension through drug:membrane interactions. Curr. Top. Med. Chem. 4 (2004) 445-459
54. McCloskey M.A., and Poo M.M. Rates of membrane-associated reactions: reduction of dimensionality revisited. J. Cell. Biol. 102 (1986) 88-96
55. Moroder L., Romano R., Guba W., Mierke D.F., Kessler H., Delporte C., Winand J., and Christophe J. New Evidence for membrane-bound pathway in hormone receptor binding. Biochemistry 32 (1993) 13551-13559
56. Moroder L., and Romano R. Synthesis, conformational and biological properties of lipophilic derivatives of gastrin and cholecystokinin peptides. Pure Appl. Chem. 66 (1994) 2111-2114
57. Moroder L. On the mechanism of hormone recognition and binding by the CCK-B/gastrin receptor. J. Pept. Sci. 3 (1997) 1-14
58. Murphy J.W., and Kendall D.A. Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55, 940 but not SR 141716A. Biochem. Pharmacol. 65 (2003) 1623-1631
59. Nials A.T., Ball D.I., Butchers P.R., Coleman R.A., Humbles A.A., Johnson M., and Vardey C.J. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur. J. Pharmacol. 251 (1994) 127-135
60. Oliveira C.R., Lima M.C.P., Carvalho C.A.M., Leysen J.E., and Carvalho A.P. Partition coefficients of dopamine antagonists in brain membranes and liposomes. Biochem. Pharmacol. 38 (1989) 2113-2120
61. 2L-receptor interactions in intact cells. Biochem. Pharmacol. 75 (2008) 2192-2203
62. Peterson B.Z., and Catterall W.A. Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 channels are modulated by calcium in the pore. Mol. Pharmacol. 70 (2006) 667-675
63. Price M.R., Baillie G.L., Thomas A., Stevenson L.A., Easson M., Goodwin R., McLean A., McIntosh L., Goodwin G., Walker G., Westwood P., Marrs J., Thomson F., Cowley P., Christopoulos A., Pertwee R.G., and Ross R.A. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68 (2005) 1484-1495
64. Rhodes D.G., Sarmiento J.G., and Herbette L.G. Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site. Mol. Pharmacol. 27 (1985) 612-623
65. Rhodes D.G., Newton R., Butler R., and Herbette L. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. Mol. Pharmacol. 42 (1992) 596-602
66. Rocha e Silva. A thermodynamic approach to problems of drug antagonism. I. The "Charnière theory". Eur. J. Pharmacol. 6 (1969) 294-302
67. Romano R., Musiol H.J., Weyher E., Dufresne M., and Moroder L. Peptide hormone-membrane interactions: the aggregational and conformational state of lipo-gastrin derivatives and their receptor binding affinity. Biopolymers 32 (1992) 1545-1558
68. Sargent D.F., and Schwyzer R. Membrane lipid phase as catalyst for peptide-receptor interactions. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 5774-5778
69. Sargent D.F., Bean J.W., and Schwyzer R. Conformation and orientation of regulatory peptides on lipid membranes. Key to the molecular mechanism of receptor selection. Biophys. Chem. 31 (1988) 183-193
70. Schwyzer R. 100 years lock-and-key concept: are peptide keys shaped and guided to their receptors by the target cell membrane?. Biopolymers 37 (1995) 5-16
71. 2-adrenoceptor agonist salmeterol. Br. J. Pharmacol., in press.
72. 7 serotonin receptor. Mol. Pharmacol. 70 (2006) 1264-1270
73. Spivak C.E., Oz M., Beglan C.L., and Shrager R.I. Diffusion delays and unstirred layer effects at monolayer cultures of Chinese hamster ovary cells: radioligand binding, confocal microscopy, and mathematical simulations. Cell. Biochem. Biophys. 45 (2006) 43-58
74. Stone S.R., Mierke J.F., and Jackson G.E. Evidence for a C-terminal structural motif in gastrin and its bioactive fragments in membrane mimetic media. Peptides 28 (2007) 1561-1571
75. Teschemacher A., and Lemoine H. Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J. Pharmacol. Exp. Ther. 288 (1999) 1084-1092
76. Theodoropoulou E., and Marsh D. Interactions of angiotensin II non-peptide antagonist losartan with phospholipid membranes by combined use of differential scanning calorimetry and electron spin resonance spectroscopy. Biochim. Biophys. Acta 1461 (1999) 135-146
77. Tian X., Guo J., Yao F., Yang D.P., and Makriyannis A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J. Biol. Chem. 280 (2005) 29788-29795
78. Tummino P.J., and Copeland R.A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47 (2008) 8465
79. Vargová L., and Syková E. Extracellular space diffusion and extrasynaptic transmission. Physiol. Res. 57 (2008) S89-S99
80. Vauquelin G., and Van Liefde I. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation. Trends Pharmacol. Sci. 51 (2006) 254-260
81. Vauquelin G., and Szczuka A. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation. Neurochem. Int. 51 (2007) 254-260
82. 2-adrenoceptor agonists in asthma: molecular pharmacological aspects. Thesis, Vrije Universiteit, Amsterdam.
83. Wang D., Gou S.Y., and Axelrod D. Reaction rate enhancement by surface diffusion of adsorbates. Biophys. Chem. 43 (1992) 117-137
84. Xie X.Q., Melvin L.S., and Makriyannis A. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J. Biol. Chem. 271 (1996) 10640-10647
85. 1 receptor. Chem. Phys. Lipids 125 (2003) 13-25